Cost-effectiveness analysis of first-line versus second-line use of CDK4/6 inhibitors combined with endocrine therapy in advanced HR+/HER2- breast cancer in China: based on the SONIA trial.

ABSTRACT:

Background

The optimal sequencing of CDK4/6 inhibitors combined with endocrine therapy for advanced hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer remains uncertain, particularly in resource-limited settings such as China. This study evaluated the cost-effectiveness of first-line versus second-line CDK4/6 inhibitor use based on the SONIA trial.

Methods

A partitioned survival model was developed to compare costs and effectiveness of first-line (CDK4/6i-first) versus second-line (CDK4/6i-second) CDK4/6 inhibitor strategies among Chinese women with advanced HR+/HER2- breast cancer. Model inputs were derived from the SONIA trial and Chinese healthcare data. Outcomes included total costs, life years (LYs), quality-adjusted life years (QALYs), and incremental c

SUBMITTER: Jin X 

PROVIDER: S-EPMC12689296 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature